Thyroid Cancer Benefits the Prognosis of Ovarian Cancer: A SEER-Based Study
To explore the effect of a second thyroid cancer (TC) on ovarian cancer (OC) patient survival, we compared OC patients with or without a second primary TC using data from the Surveillance, Epidemiology, and End Results (SEER) database.
Data for OC only, female TC only and OC patients with a second TC (OC2TC) from two periods, 2000–2014 and 1980–1994, were extracted from the SEER database. Differences in clinicopathological and treatment characteristics were analysed using the chi-square test. Cox regression analyses were used to identify risk factors associated with OC survival. Disease-specific survival (DSS) and overall survival (OS) curves were compared using the log-rank test.
There were 109 OC2TC patients from 2000 to 2014, and significant differences (P < 0.001) in the mean age at OC diagnosis, TNM stage and surgical history were found between OC and OC2TC patients. Several factors, including age, grade, TNM stage, histological type and surgical history, influenced OC survival (P < 0.001). OC2TC patients showed better survival than OC patients from 2000 to 2014, regardless of age, TNM stage or surgical history. However, this superiority was not significant in cases from 1980 to 1994 (P = 0.222 for OS).
Survival was better with OC2TC than with OC from 2000 to 2014 rather than 1980–1994, suggesting that TC improved the survival of OC patients from 2000 to 2014.
KeywordsOvarian cancer Survival Thyroid cancer TSH suppression therapy
This study was funded by the Natural Science Foundation of Zhejiang Province of China (grant numbers LY13H160039 and LY18H160039) and the Traditional Chinese Medicine Science and Technology Project of Zhejiang Province of China (grant number C-2013-W209). The sponsors also partially funded the article processing charges.
This manuscript was edited for proper English language, grammar, punctuation, spelling, and overall style by one or more of the highly qualified native English-speaking editors at American Journal Experts.
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Qiong Yang, Zhiyong Wu, Xujun He, Leibo Yu, Xiaofei Zhang and Kefeng Lei have nothing to disclose.
Compliance with Ethics Guidelines
All SEER data were accessed with approval from the SEER database and, as such, this article does not contain any studies with human participants or animals performed by any of the authors.
The datasets analysed during the current study are available from the corresponding author on reasonable request.
- 2.Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics review, 1975–2014, based on November 2016 SEER data submission, posted to the SEER web site, April 2017. MD: National Cancer Institute Bethesda; 2017.Google Scholar
- 3.NCCN. National Comprehensive Cancer Network (NCCN) guidelines for OC, version 4.2017. 2017. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed 9 Nov 2017.
- 19.American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214. https://doi.org/10.1089/thy.2009.0110.CrossRefGoogle Scholar
- 21.Carrera MP, Ramirez-Exposito MJ, Valenzuela MT, et al. Pyrrolidon carboxypeptidase activities in the hypothalamus–pituitary–thyroid and hypothalamus–pituitary–ovary axes of rats with mammary gland cancer induced by N-methyl nitrosourea. Horm Metab Res. 2005;37(2):74-8. https://doi.org/10.1055/s-2005-861158.CrossRefGoogle Scholar